Table 2.

Adverse events reported in phase III trials with pegylated liposomal doxorubicin (PLD)

Study	Grade 3–4 hematological toxicity		Grade 3–4 nonhematological toxicity
Gordon et al 20011	Neutropenia	12%	PPE	23%
	Anemia	5%	Stomatitis	8.3%
	Thrombocytopenia	1%
Mutch et al 200741	Neutropenia	18%	PPE	10.4%
	Febrile neutropenia	4%	Mucositis	3.1%
	Anemia	2%
	Thrombocytopenia	5%
Ferrandina et al 200842	Neutropenia	6%	PPE	5%
	Anemia	5%	Stomatitis	3%
	Thrombocytopenia	0%
Pignata et al 200683	Neutropenia	46%	PPE	2%
	Anemia	16%	Stomatitis	0
	Thrombocytopenia	26%

Abbreviation: PPE, plantar palmar erythema.